AZD2461: A Novel PARP Inhibitor for Advanced Breast Cancer Research

Executive Summary: AZD2461 is a potent PARP inhibitor (IC50 = 5 nM) targeting DNA repair in cancer cells, notably breast cancer models (APExBIO). It induces cytotoxicity and G2 phase cell cycle arrest in MCF-7 and SKBR-3 lines. Unlike olaparib, AZD2461 displays reduced affinity for P-glycoprotein, potentially overcoming multidrug resistance (Schwartz 2022). In vivo, it prolongs relapse-free survival in tumor-bearing mice. AZD2461 is insoluble in water but highly soluble in DMSO and ethanol, supporting flexible in vitro workflows.

Biological Rationale

Poly (ADP-ribose) polymerase (PARP) enzymes, especially PARP-1, are integral to cellular DNA repair pathways. Inhibition of PARP disrupts repair of single-strand DNA breaks, which can induce double-strand breaks and apoptosis in cancer cells—particularly those deficient in homologous recombination (e.g., BRCA1 mutations) (Schwartz 2022). Targeting PARP is a validated approach for sensitizing tumor cells to DNA-damaging therapies and limiting repair-driven resistance mechanisms. AZD2461 is a structurally novel PARP inhibitor developed to address limitations of earlier agents, notably multidrug resistance conferred by P-glycoprotein (Pgp) activity. This compound is especially relevant for breast cancer research, where DNA repair modulation and drug resistance pose major clinical and translational challenges (see Mechanistic Insights and Strategic Pathways).

Mechanism of Action of AZD2461

AZD2461 is a synthetic inhibitor of PARP-1, acting at nanomolar potency (IC50 = 5 nM). Upon cellular entry, it competes with NAD⁺ at the PARP-1 catalytic site, blocking poly (ADP-ribosyl)ation and the recruitment of DNA repair complexes. In human breast cancer cell lines MCF-7 and SKBR-3, AZD2461 treatment reduces viable cell numbers in a time- and concentration-dependent manner. This cytotoxicity is accompanied by G2 phase cell cycle arrest and a reduction in S phase population as assessed by flow cytometry after 48–72 hours of exposure (5–50 μM) (Schwartz 2022). In vivo, AZD2461 administration in KB1P mouse tumor models results in acute PARP inhibition, with cellular PAR levels suppressed for several hours before returning to baseline within 24 hours. Uniquely, AZD2461 demonstrates lower Pgp affinity than olaparib, enhancing tissue penetration and reducing efflux-mediated resistance (see Novel PARP Inhibitor for Breast Cancer Research for further discussion).

Evidence & Benchmarks

• AZD2461 inhibits PARP-1 enzymatic activity with an IC50 of 5 nM in vitro (APExBIO).
• Cytotoxicity observed in MCF-7 and SKBR-3 breast cancer cell lines in a concentration- and time-dependent fashion (5–50 μM, 48–72 h) (Schwartz 2022).
• AZD2461 causes cell cycle arrest, increasing G2 phase and decreasing S phase fractions in treated cells (Schwartz 2022).
• In vivo, PARP activity in KB1P mouse tumors is suppressed for several hours post-dose, with PAR levels normalizing by 24 h (Schwartz 2022, Figure/Table: In vivo PARP inhibition).
• AZD2461 exhibits lower P-glycoprotein (Pgp) affinity than olaparib, improving efficacy in multidrug-resistant cancer models (Strategic Deployment of AZD2461).
• Chronic administration in murine models is well tolerated and significantly extends median relapse-free survival (Schwartz 2022).
• AZD2461 is insoluble in water but dissolves in DMSO (≥16.35 mg/mL) and ethanol (≥45.2 mg/mL with ultrasound), supporting diverse in vitro protocols (APExBIO).

Applications, Limits & Misconceptions

AZD2461 is primarily used in the preclinical evaluation of DNA repair pathway modulation, especially in breast cancer models. Its low Pgp affinity makes it suitable for studies focusing on multidrug resistance. The compound is suitable for both in vitro and in vivo workflows, including assessment of cytostatic and cytotoxic effects as recommended by recent advances in drug response quantification (Schwartz 2022). Compared to related agents, AZD2461 offers distinct advantages in Pgp-mediated resistance and tolerability, as detailed in Redefining PARP Inhibition for Advanced Breast Cancer, which this article updates by providing direct evidence-based benchmarks and protocol-specific solubility data.

Common Pitfalls or Misconceptions

• Not for clinical use: AZD2461 is for research use only and is not approved for therapeutic administration in humans (APExBIO).
• Solubility limitations: The compound is insoluble in water and must be prepared in DMSO or ethanol for experiments.
• Short-term solution stability: Working solutions are recommended for immediate use; prolonged storage may result in compound degradation.
• Cell line specificity: Most published data are derived from breast cancer models; results may not generalize to all cancer types.
• Limited resistance models: While effective against Pgp-mediated resistance, other resistance mechanisms (e.g., non-Pgp efflux or DNA repair redundancy) may reduce efficacy.

Workflow Integration & Parameters

AZD2461 is provided as a solid (C₂₂H₂₂FN₃O₃, MW 395.43). For in vitro use, dissolve in DMSO (≥16.35 mg/mL) or ethanol (≥45.2 mg/mL with ultrasonic assistance). Store at -20°C and use solutions immediately. Typical experimental concentrations are 5–50 μM with incubation times of 48–72 hours (APExBIO). Assay endpoints include cell viability (e.g., MTT, CellTiter-Glo), cell cycle analysis (flow cytometry), and PARP activity quantification (ELISA or immunoblot). For in vivo studies, dosing regimens and treatment durations should be referenced from published murine models, ensuring ethical and regulatory compliance. This article extends the strategic framework outlined in Advancing Breast Cancer Research Through Next-Gen PARP Inhibition by providing updated protocols and solubility guidance.

Conclusion & Outlook

AZD2461, available from APExBIO, is a validated tool for preclinical studies of PARP inhibition in breast cancer and multidrug-resistant tumor models. Its low IC50, effective cell cycle arrest, and reduced Pgp affinity address key limitations of earlier PARP inhibitors. Ongoing research should extend investigation to additional cancer types and explore combination regimens. For protocols, troubleshooting, and strategic deployment, see also Mechanistic Insights and Strategic Pathways, which this article clarifies by highlighting in vivo benchmarks and compound handling best practices.